Statements (75)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Herceptin
|
| gptkbp:activities |
inhibits HE R2 signaling
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:1998
gptkb:FDA |
| gptkbp:associated_with |
lower recurrence rates
|
| gptkbp:can_be_used_with |
chemotherapy
|
| gptkbp:capacity |
10 m L
|
| gptkbp:clinical_trial |
gptkb:trastuzumab-dttb
Phase III metastatic breast cancer early-stage breast cancer |
| gptkbp:developed_by |
gptkb:Genentech
|
| gptkbp:financial_performance |
refrigerated storage
|
| gptkbp:frequency |
every 3 weeks
|
| https://www.w3.org/2000/01/rdf-schema#label |
trastuzumab-qyzy
|
| gptkbp:impact |
improves overall survival
|
| gptkbp:indication |
HE R2-positive breast cancer
|
| gptkbp:influences |
T-cell activation
apoptosis cellular stress response immune response tumor heterogeneity tumor microenvironment angiogenesis epigenetic modifications cellular signaling pathways cell cycle arrest chemoresistance immune evasion metabolic reprogramming gene expression profiles therapeutic resistance mechanisms NK cell activity radiation sensitivity B-cell response monocyte recruitment tumor evolution dendritic cell maturation cytokine release tumor microenvironment remodeling tumor growth inhibition tumor-associated macrophages Treg cell function cancer stem cell dynamics cytokine milieu immune checkpoint expression immune checkpoint modulation macrophage polarization metastatic potential tumor antigen presentation tumor immune landscape |
| gptkbp:ingredients |
C6464 H9912 N1716 O1980 S44
|
| gptkbp:invention |
patented
|
| gptkbp:is_available_on |
lyophilized powder
|
| gptkbp:is_used_for |
treatment of breast cancer
|
| gptkbp:manager |
subcutaneous
|
| gptkbp:marketed_as |
gptkb:Herceptin
|
| gptkbp:produced_by |
Chinese hamster ovary cells
|
| gptkbp:provides_information_on |
NCCN guidelines
|
| gptkbp:research_focus |
HE R2-positive gastric cancer
|
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
fatigue
headache nausea diarrhea rash infusion reactions cardiotoxicity |
| gptkbp:targets |
HE R2 protein
|
| gptkbp:used_in |
adjuvant therapy
neoadjuvant therapy |
| gptkbp:weight |
146 k Da
|